Heart failure in patients with human immunodeficiency virus: A review of the literature

Journal of Cardiovascular Medicine

Volumn 16, Issue 5, 2015, Pages 383-389

  Cannillo, Margherita ^a   D'Ascenzo, Fabrizio ^a   Grosso Marra, Walter ^a   Cerrato, Enrico ^a   Calcagno, Andrea ^b   Omedè, Pierluigi ^a   Bonora, Stefano ^b   Mancone, Massimo ^c   Vizza, Dario ^c   Dinicolantonio, James J ^d   Pianelli, Martina ^a   Barbero, Umberto ^a   Gili, Sebastiano ^a   Annone, Umberto ^a   Raviola, Alessio ^a   Salera, Davide ^a   Mistretta, Elisa ^a   Vilardi, Ilaria ^a   Colaci, Chiara ^a   Abbate, Antonio ^e   Zoccai, Giuseppe Biondi ^c   Moretti, Claudio ^a   Gaita, Fiorenzo ^a   more..

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c POLICLINICO UMBERTO I   (Italy)

^d Wegmans Pharmacy   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

cardiovascular magnetic resonance; late gadolinium enhancement; left atrium

Indexed keywords

CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; INFECTION; NONHUMAN; PATHOPHYSIOLOGY; PROGNOSIS; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SUDDEN CARDIAC DEATH; VIRUS LOAD; ADVERSE EFFECTS; COMPLICATION; HIV INFECTIONS; MASS SCREENING; PROCEDURES; VIROLOGY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HEART FAILURE; HIV INFECTIONS; HUMANS; INCIDENCE; MASS SCREENING; PROGNOSIS; RISK FACTORS; VIRAL LOAD;

EID: 84926406819     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0000000000000168     Document Type: Review

References (67)

1. Andrieux-Meyer I, Calmy A, Cahn P, et al., Art Sequencing meeting September 22-23, 2011, Geneva, Switzerland. Preferred antiretroviral drugs for the next decade of scale up. J Int AIDS Soc 2012; 15:17986
2. Aberg JA. Aging, inflammation, and HIV infection. Top Antivir Med 2012; 20:101-105
3. DAscenzo F, Cerrato E, Biondi-Zoccai G, et al. Acute coronary syndromes in human immunodeficiency virus patients: a meta-analysis investigating adverse event rates and the role of antiretroviral therapy. Heart J 2012; 33:875-880
4. Biondi-Zoccai G, DAscenzo F, Modena MG. Novel insights on HIV/AIDS and cardiac disease: shedding light on the HAART of Darkness. Eur Heart J 2012; 33:813-815
5. Butt AA, Chang CC, Kuller L, et al. Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch Intern Med 2011; 171:737-743
6. Hsu JC, Li Y, Marcus GM, Hsue PY, Scherzer R, Grunfeld C, Shlipak MG. Atrial fibrillation and atrial flutter in human immunodeficiency virus-infected persons: incidence, risk factors, and association with markers of HIV disease severity. J Am Coll Cardiol 2013; 61:2288-2295
7. Tseng ZH, Secemsky EA, Dowdy D, et al. Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol 2012; 59:1891-1896
8. Cohen IS, AnDerson DW, Virmani R, et al. Congestive cardiomyopathy in association with the acquired immunodeficiency syndrome. N Engl J Med 1986; 315:628-630
9. Barbaro G. Cardiovascular manifestations of HIV infection. Circulation 2002; 106:1420-1425
10. Barbaro G, Fisher SD, Lipshultz SE. Pathogenesis of HIV-associated cardiovascular complications. Lancet Infect Dis 2001; 1:115-124
11. Cole JW, Pinto AN, Hebel JR, et al. Acquired immunodeficiency syndrome and the risk of stroke. Stroke 2004; 35:51-56
12. Boccara F, Lang S, Meuleman C, et al. HIV and coronary heart disease: time for a better unDerstanding. J Am Coll Cardiol 2013; 61:511-523
13. Xiong D, Yajima T, Lim BK, et al. Inducible cardiac-restricted expression of enteroviral protease 2A is sufcient to induce dilated cardiomyopathy. Circulation 2007; 115:94-102
14. Yajima T, Yasukawa H, Jeon ES, et al. Innate defense mechanism against virus infection within the cardiac myocyte requiring gp130-STAT3 signaling. Circulation 2006; 114:2364-2373
15. Kaya Z, Leib C, Katus HA. Autoantibodies in heart failure and cardiac dysfunction. Circ Res 2012; 110:145-158
16. Dabrowska MM, Mikula T, Wiercinska-Drapalo A. HCV coinfection possibly promotes left ventricular dysfunction development: analysis of brain natriuretic peptide serum levels in HCV/HIV-coinfected and HIVmonoinfected patients. Eur J Gastroenterol Hepatol 2012; 24:1308-1312
17. Grouillette J, Grandy SA, Jolicoeur P, Fiset C. Cardiac repolarization is prolonged in CD4C/HIV transgenic mice. J Mol Cell Cardiol 2007; 43:159-167; [PubMed: 17597146].
18. Grandy SA, Brouillette J, Fiset C. Reduction of ventricular sodium current in a mouse model of HIV. J Cardiovasc Electrophysiol 2010; 21:916-922; [PubMed: 20132381].
19. JericoC, Knobel H, Montero M, et al. Hypertension in HIV-infected patients: prevalence and related factors. Am J Hypertens 2005; 18:1396-1401
20. Seaberg EC, Munoz A, Lu M, et al., Multicenter AIDS Cohort Study. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 2005; 19:953-960
21. Crane HM, Van Rompaey SE, Kitahata MM. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS 2006; 20:1019-1026
22. Esser S, Gelbrich G, Brockmeyer N, et al. Prevalence of cardiovascular diseases in HIV-infected outpatients: results from a prospective, multicenter cohort study. Clin Res Cardiol 2013; 102:203-213
23. Ucciferri C, Falasca K, Mancino P, Di Iorio A, Vecchiet J. Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan. Eur Rev Med Pharmacol Sci 2012; 16:491-498
24. Rose H, Hoy J, Woolley I, Tchoua U, Bukrinsky M, Dart A, Sviridov D. HIV infection and high density lipoprotein metabolism. Atherosclerosis 2008; 199:79-86
25. Anastos K, Lu D, Shi Q, et al. Association of serum lipid levels with HIV serostatus, specic antiretroviral agents, and treatment regimens. J Acquir Immune Dec Syndr 2007; 45:34-42
26. Asztalos BF, Schaefer EJ, Horvath KV, et al. Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients. Atherosclerosis 2006; 184:72-77
27. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. J Am Med Assoc 2003; 289:2978-2982
28. Brown TT, Li X, Cole SR, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005; 19:1375-1383
29. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165:1179-1184
30. Justman JE, Benning L, Danoff A, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 2003; 32:298-302
31. Lewis W, Simpson JF, Meyer RR. Cardiac mitochondrial DNA polymerasegamma is inhibited competitively and noncompetitively by phosphorylated zidovudine. Circ Res 1994; 74:344-348
32. Lipshultz SE, Orav EJ, SanDers SP, Hale AR, McIntosh K, Colan SD. Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine. N Engl J Med 1992; 327:1260-1265
33. Barnett CF, Hsue PY. Human immunodeficiency virus-associated pulmonary arterial hypertension. Clin Chest Med 2013; 34:283-292
34. Kanmogne GD, Primeaux C, Grammas P. Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. Biochem Biophys Res Commun 2005; 333:1107
35. Humbert M, Monti G, Fartoukh M, et al. Platelet-Derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998; 11:554-559
36. Mette SA, Palevsky HI, Pietra GG, et al. Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am Rev Respir Dis 1992; 145:1196-1200
37. Degano B, Guillaume M, Savale L, et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the moDern therapeutic era. AIDS 2010; 24:67-75
38. Petrosillo N, Chinello P, Vizza D, Cicalini S. Pulmonary hypertension and HIV: implementation of a Regional Registry. Infez Med 2005; 13: 5-15
39. Cerrato E, DAscenzo F, Biondi-Zoccai G, et al. Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a metaanalysis in the highly active antiretroviral therapy era. Eur Heart J 2013; 34:1432-1436
40. Schnabel RB, Rienstra M, SulliVan LM, et al. Risk assessment for incident heart failure in individuals with atrial fibrillation. Eur J Heart Fail 2013; 15:843-849
41. DAscenzo F, Corleto A, Biondi-Zoccai G, et al. Which are the most reliable predictors of recurrence of atrial fibrillation after transcatheter ablation?: a meta-analysis. Int J Cardiol 2013; 167:1984-1989
42. Chatterjee S, Biondi-Zoccai G, Abbate A, et al. Benefits of b blockers in patients with heart failure and reduced ejection fraction: network metaanalysis. BMJ 2013; 346:f55
43. Swedberg K, Komajda M, Böhm M, Borer J, Robertson M, Tavazzi L, Ford I, SHIFT Investigators. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol 2012; 59:1938-1945
44. Volberding PA, Murphy RL, Barbaro G, et al. The Pavia consensus statement. AIDS 2003; 17 (Suppl 1):S170-S179
45. Friis-Mller N, Thiebaut R, Reiss P, et al., DAD study group. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil 2010; 17:491-501, http://www.cuore.iss.it/
46. Breuckmann F, Nassenstein K, Kondratieva J, et al., German Heart Failure Network; Competence Network HIV/AIDS. MR characterization of cardiac abnormalities in HIVindividuals with increased BNP levels. Eur J Med Res 2007; 12:185-190
47. Barbaro G, Iacobellis G. Metabolic syndrome associated with HIV and highly active antiretroviral therapy. Curr Diab Rep 2009; 9:37-42
48. Iacobellis G, Sharma AM, Pellicelli AM, Grisorio B, Barbarini G, Barbaro G. Epicardial adipose tissue is related to carotid intima-media thickness and visceral adiposity in HIV-infected patients with highly active antiretroviral therapy-associated metabolic syndrome. Curr HIV Res 2007; 5:275-279
49. Iacobellis G, Pellicelli AM, Sharma AM, Grisorio B, Barbarini G, Barbaro G. Relation of subepicardial adipose tissue to carotid intima-media thickness in patients with human immunodeficiency virus. Am J Cardiol 2007; 99:1470-1472
50. Iacobellis G, Pellicelli AM, Grisorio B, Barbarini G, Leonetti F, Sharma AM, Barbaro G. Relation of epicardial fat and alanine aminotransferase in subjects with increased visceral fat. Obesity (Silver Spring) 2008; 16:179-183
51. Fiorentini A, Petrosillo N, Di Stefano A, et al. QTc interval prolongation in HIV-infected patients: a case-control study by 24-h Holter ECG recording. BMC Cardiovasc Disord 2012; 12:124
52. Curtis JP, Rathore SS, Wang Y, Krumholz HM. The association of 6-min walk performance and outcomes in stable outpatients with heart failure. J Card Fail 2004; 10:9-14
53. Hsu CH, Glassner C, Foreman AJ, Agarwal R, Benza RJ, Frantz RP, Gomberg-Maitland M. Treadmill testing improves survival prediction models in pulmonary arterial hypertension. Am Heart J 2011; 162:1011-1017
54. Beatty AL, Schiller NB, Whooley MA. Six-minute walk test as a prognostic tool in stable coronary heart disease: data from the heart and soul study. Arch Intern Med 2012; 172:1096-1102
55. Holloway CJ, Ntusi N, Suttie J, et al. Comprehensive cardiac magnetic resonance imaging and spectroscopy reveal a high burden of myocardial disease in HIV patients. Circulation 2013; 128:814-822
56. Lai H, Redheuil A, Tong W, Bluemke DA, Lima JA, Ren S, Lai S. HIV infection and abnormal regional ventricular function. Int J Cardiovasc Imaging 2009; 25:809-817
57. Kjaer A, Lebech AM, Gerstoft J, Hesse B, Petersen CL. Right ventricular volume and mass determined by cine magnetic resonance imaging in HIV patients with possible right ventricular dysfunction. Angiology 2006; 57:341-346
58. Lauer M, Froelicher ES, Williams M, Kligfield P, American Heart Association Council on Clinical Cardiology, Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Exercise testing in asymptomatic adults: a statement for professionals from the American Heart Association Council on Clinical Cardiology, Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation 2005; 112:771-776
59. Christian JB, Finkle JK, Ky B, et al. Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction. Am Heart J 2012; 164:846-855
60. DAscenzo F, Cerrato E, Biondi-Zoccai G, et al. Coronary computed tomographic angiography for detection of coronary artery disease in patients presenting to the emergency department with chest pain: a metaanalysis of randomized clinical trials. Eur Heart J Cardiovasc Imaging 2013; 14:782-789
61. Vizza CD, Sciomer S, Morelli S, et al. Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue. Heart 2001; 86:661-665
62. Martinez T, Sztajzel J. Utility of event loop recorDers for the management of arrhythmias in young ambulatory patients. Int J Cardiol 2004; 97:495-498
63. Marzolini C, Elzi L, Gibbons S, et al., Swiss HIV Cohort Study. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther 2010; 15:413-423, www.hiv-druginteractions.org
64. Krishan K, Pinney S, Anyanwu AC. Successful left ventricular assist device bridge to transplantation in a patient with end-stage heart failure and human immunodeficiency virus. Artif Organs 2012; 36:759
65. Bosch X, Rovira M, Sitges M, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: The OVERCOME Trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol 2013; 61:2355-2362
66. Sliwa K, Carrington MJ, Becker A, Thienemann F, Ntsekhe M, Stewart S. Contribution of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic to de novo presentations of heart disease in the Heart of Soweto Study cohort. Eur Heart J 2012; 33:866-874
67. Ntsekhe M, Hakim J. Impact of human immunodeficiency virus infection on cardiovascular disease in Africa. Circulation 2005; 112:3602-3607